Outcomes
CMD, depression
The primary outcome was mean adherence between 2 to 6 months of follow-up. Secondary outcomes included mean adherence between 1 to 12 months; change from baseline SSQ-14 and PHQ-9 score at 3, 6, 9, and 12 months; and change in viral suppression (viral load <1000 copies per mL) at months 6 and 12; and positive screening for CMD (SSQ-14 score ≥9) and depression (PHQ-9 score ≥11) at 3, 6, 9, and 12 months.